1 Metabolomic Risk Predictors of Diabetic Foot Complications: a longitudinal

2 observational study in Type 1 Diabetes

- 3
- 4 Jonas A. Andersen^{1†}, Tommi Suvitaival^{1†}, Kajetan Trošt¹, María José Romero-Lado¹, Simone
- 5 Theilade^{1,2,3}, Ismo Mattila¹, Marie Frimodt-Møller¹, Anne Rasmussen¹, Peter Rossing^{1,3}, Cristina
- 6 Legido-Quigley¹, Tarunveer S. Ahluwalia^{1,4,5*}

7 Affiliations:

- 8 ¹Steno Diabetes Center Copenhagen, Herlev, Denmark
- 9 ²Department of Medicine, Herlev-Gentofte Hospital, Copenhagen, Denmark
- ³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- ⁴The Bioinformatics Center, Department of Biology, University of Copenhagen, Copenhagen,
- 12 Denmark
- ⁵Department of Science and Environment, Roskilde University, Roskilde, Denmark
- [†]These authors contributed equally to this work
- 15

16 ***Corresponding author:**

- 17 Tarunveer Singh Ahluwalia, PhD.
- 18 Senior Researcher & Associate Professor
- 19 Steno Diabetes Center Copenhagen
- 20 Borgmester Ib Juuls Vej 83
- 21 DK-2730 Herlev
- 22 Phone: +45 20558294
- 23 Email: tarun.veer.singh.ahluwalia@regionh.dk
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38 39
- 40 Word count: Main text: 2878 Abstract: 248
- 41 **Number of tables and figures**: One table & three figures

42 Abstract:

43 Diabetic foot complications (DFCs) comprising diabetic foot ulcer (DFU), charcot's 44 neuroarthropathy and amputations are a collective term used for the ailments of the foot that 45 individuals with diabetes incur. Despite implementation of national and international guidelines, 46 DFCs are still a growing challenge to the individual and society. Novel markers for the treatment 47 and prevention of DFCs are thus needed. The aim of this study was to investigate circulating 48 metabolites associated with the prevalence and incidence of DFCs in persons with type 1 diabetes 49 (T1D). A panel of non-targeted serum metabolites (n=75) were analyzed using mass spectrometry 50 in 637 individuals with T1D with a median follow up time of 10 years. Cross sectional associations 51 between metabolites and DFCs were analysed by linear regression models at baseline, Cox 52 proportional hazards model at follow-up and adjusted for relevant confounders (age, sex, Hb_{Alc}, 53 systolic blood pressure, bmi, smoking, statin use, total cholesterol, plasma triglycerides, and renal 54 function). The median (interquartile range) age was 55 (47, 64) years, diabetes duration of 35 (25, 55 44) years and HbA_{1c} levels 64 (8%) (56, 72(7.3%, 8.7%)) mmol/mol. In the adjusted model, four 56 amino acids (Proline, Threonine, Valine, and Leucine) were associated with a decreased incidence 57 of Charcot's arthropathy at baseline (p < 0.05). In addition, circulating ribonic acid levels were 58 associated with an increased risk of DFUs during follow-up (HR 1.38(1.06-1.8); p<0.05) which 59 were validated in an independent cross-sectional T1D cohort (p<0.05). This study identifies novel 60 circulating metabolites, as potential biomarkers for risk stratification of diabetic foot complications.

- 61
- 62
- 63
- 64
- 65

66 *Keywords:* Metabolomics, diabetic foot complications, diabetic foot ulcer, amputation, Charcot

67 Introduction

68 The complications that afflict the feet of individuals with diabetes are often referred to under the 69 common term diabetic foot complications. Generally, the term covers four ailments that afflict the 70 diabetic foot; diabetic foot ulcers (DFU), infections of the diabetic foot, amputations incurred by 71 individuals with diabetes and Charcot's arthropathy. The ailments encompassed in the term are 72 closely linked to each other; and with a lifetime risk of 19-34% the DFU is the most common 73 diabetic foot complication incurred by individuals with diabetes(1). The DFU is often the triggering 74 event for infections and amputations of the diabetic foot(1) and has been associated to risk of 75 Charcot's arthropathy(2). Apart from the connection between the individual ailments of the diabetic 76 foot, the diabetic foot borrows from both the macro and microvascular complications of diabetes 77 with connections to neuropathy, peripheral arterial disease and retinopathy among others(3). To put 78 the challenge in perspective an individual with diabetes is subjected to amputation of the lower limb 79 or part of a lower limb every 30 sec. on a global scale(4). In addition to the burden incurred by the 80 individual, the diabetic foot complication poses a significant economic challenge to all societies in 81 the world. The cost of treating the diabetic foot complication is substantial, with a 5.4 times higher 82 cost of treating an individual with a diabetic foot complication compared to an individual with 83 diabetes without a foot complication(5). On a larger scale 1% of the total health-care budget in 84 England was spend on treating the diabetic foot(6). These challenges have led to several national 85 and international strategies with the intend of reducing the incidence of diabetic foot 86 complications(7). This has, however, not lead to a significant reduction in the incidence or cost of 87 diabetic foot complications in general. In addition, the projected increase in size and lifespan of the 88 global diabetic population, new treatment strategies are needed to incur reductions in or even 89 prevention of prevention of diabetic foot complications(3).

One of the emerging frontiers in prevention and treatment of the diabetic foot complication is metabolomics. Metabolomics has shown promise in identifying pathways and biomarkers associated with risk of developing diabetes(8; 9). Furthermore, specific metabolites have been associated with increased risk of developing complications associated with diabetes(10). Despite the increased focus on the relationship between metabolomics and diabetic complications, studies on this topic are still lacking.

Thus, the aim of the current study was to investigate the association between a non-targeted panel of circulating serum metabolites and three severe forms of diabetic foot complications (DFU, amputations and Charcot's arthropathy (form here on referred to as diabetic foot complications or DFCs)) among adult persons with type 1 diabetes (T1D).

100 Research Design and Methods

101 637 individuals with T1D and a wide range of albuminuria were recruited from the outpatient clinic

102 at Steno Diabetes Center Copenhagen (SDCC).

103 This is a longitudinal observational cohort recruited between 2009 and 2011. Details of this cohort 104 have been previously described (11).

105 Another cross-sectional observational cohort with 161 T1D individuals being followed at SDCC

and recruited during 2016-2017, also described in detail previously (12), was used as the validationcohort.

All participants were subdivided into different albuminuria stages, normoalbuminuria (<3.39 mg/mmol corresponding to <30 mg/24 h or mg/g), moderately increased albuminuria (3.39–33.79 mg/mmol corresponding to 30–299 mg/24 h or mg/g), and severely increased albuminuria (\geq 33.90 mg/mmol corresponding to \geq 300 mg/24 h or mg/g). Participants with end stage kidney disease defined as receiving dialysis, kidney transplantation, estimated glomerular filtration rate (eGFR)< 15ml/min/1.73m² at baseline were excluded.

In the current study plasma metabolomics data along with information on (with or without) all foot complications (diabetic foot ulcer (DFU), amputation, and Charcot's arthropathy) was available for 637 individuals in the primary study whereas 126 individuals with T1D and peripheral neuropathy had information available only on DFUs (validation cohort).
The study was conducted according to the Helsinki Declaration on ethical principles for medical research. The study was approved by the Danish Ethical Committee for the Capital Region of

120 Denmark (Hillerød, Denmark), Danish Patient Safety Authorities and Danish Data Protection

121 Agency. All participants provided informed written consent.

122 Baseline Characteristics and Diagnosis Codes

123 All information on clinical characteristics and diabetic foot complications was extracted from the 124 patient's electronic health records. Three diabetic foot complications including DFUs, amputations, 125 and Charcot's arthropathy were investigated in the current study. All information on diabetic foot 126 complications were attained in accordance with the international classification of diseases, tenth 127 revision(13). A DFU was defined as a lesion of the skin on the foot of the person with type 1 128 diabetes (14). All information on procedures (amputations) were attained in accordance with 129 Danish version of the Nordic Classification of Surgical Procedures(15). Date of diabetic foot 130 complications diagnosis was cross referenced with date of participant blood sampling for 131 metabolomic and biochemical analysis (or baseline). The diagnosis was then registered as "at 132 baseline" if date of diagnosis was made prior to or at baseline and as during follow-up if date of 133 diagnosis was after baseline. eGFR was calculated using the CKD-EPI 2012 equation (16).

Participant baseline characteristics (Table 1) refer to the time point where blood collections were made for metabolomics analyses. Longitudinal data was acquired until 31st Dec 2020. Data regarding potential changes in medication during follow-up were not available.

137 Serum Metabolomics Analyses

138 The method used has previously been described in detail by Tofte et. al(17). In brief, the metabolomic measurements were performed using serum stored at -80° C. Leco Pegasus four-139 140 dimensional gas chromatography with time off flight mass spectrometry (4D GC×GC TOFMS) 141 instrument (Leco Corp. MI, USA) was used for metabolomics measurements. Using ChromaTOF 142 raw data were assessed using peak-picking and resulting data were processed (alignment and 143 normalization) with Guinea(18) and postprocessed in R-software. Inclusion of metabolites in the 144 following analysis was based on certainty of the identification and level of technical precision. No 145 restrictions for prior hypothesis or known pathways were implemented. A total of 75 metabolites 146 (ESM Table 1, Supplementary table 4.1.1.3) were measured and included in analyses. These 147 included amino acids, free fatty acids and compounds from the polyol and energy metabolite 148 pathways.

Metabolites with missing or undetectable values less than or equal to 20%, underwent imputation
using the k-nearest neighbor algorithm and were log2-transformed as previously described (17; 19).

151 Statistical analysis

152 All statistical analysis and subsequent data visualization were carried out using the R-software.

153 Continuous variables are given as median (interquartile range Q1-Q3 or IQR). Skewed variables, 154 including all metabolites were log transformed before association testing. Categorical variables are 155 given as total number followed by %. Clinical characteristics at baseline between two groups with 156 and without diabetes foot complications were compared using Welch two sample t-test, Fisher's 157 exact test or Chi-squared test for continuous or categorical variables, respectively. Circulating 158 metabolites and specific diabetic foot complication outcome were evaluated as follows: Cross 159 sectional associations between each metabolite and diabetic foot complication outcome at baseline 160 were assessed using multivariate linear regression models adjusted for relevant clinical variables.

161 The following models were used: *Crude model:* unadjusted, *M1 model* adjusted for age, gender, 162 body mass index, systolic blood pressure, cholesterol, HbA_{1c}, smoking, statin use, and triglycerides, 163 also referred to as adjusted model. *M2 model* was M1 with additional adjustment for renal function 164 markers (eGFR and/or UACR) also referred to as "fully adjusted" model. Multiple testing 165 correction for p values were perfomed using the Benjamini-Hochberg method ($p_{adjusted}$) throughout 166 the analyses.

167 Cox proportional hazards model was used to assess longitudinal follow-up end points. The hazard 168 ratios (HR) are reported per doubling of specified metabolites level. Significant or top performing 169 metabolites with P_{adjusted} <0.05 in the adjusted (M1) longitudinal cox proportional hazards model 170 were included in survival analysis with the fully adjusted cox proportional hazards (M2) model for 171 end points. The R-package "survminer" was used for constructing a) Kaplan-Meier plots for end 172 points during longitudinal follow-up with stratification on median levels of the top-performing 173 metabolite at baseline, and b) forest plot of the hazard ratios of the top-performing metabolite and 174 clinical covariates. Integration of the results from all the crude models was visualized with the R-175 package "circlize". Significance was defined as p<0.05 (before multiple testing) and padiusted<0.05 176 (after multiple testing) unless other is noted. Significance for validation cohort was defined as 177 p<0.05.

178 Results

179 Clinical characteristics of study population

The primary study included 637 participants (54.6% males) with T1D, a median (IQR) age of 55 (47-64) years, diabetes duration of 35 (25-44) years (Table 1). In the following the participants are divided in two groups; first group without any diabetic foot complication at baseline (n=577) and the second group with at least one foot complication at baseline (n=60).

Age, diabetes duration, and urinary albumin creatinine ratio (UACR) were significantly higher in T1D with foot complications compared to the T1D without foot complications group. The estimated glomerular filtration rate (eGFR) was significantly lower in the two groups with foot complications compared to the group without foot complications (Table 1).

All T1D individuals from baseline that did not incur a diabetic foot complication during a median follow up time of 10 years formed the no-foot complications group (n=488) whereas those who developed at least one foot complication during a median follow up (n=89) formed the foot complications group, for longitudinal analysis (Extra supplementary material, ESM Table 2). A total of 68 diagnoses of diabetic foot complications were registered at baseline (Table 1), while 149 new diagnoses were made during follow-up (ESM Table 2).

194 Cross-sectional analysis

All 75 circulating metabolites were included in a linear regression analysis at baseline(Supplementary file Table 4.1.1.3).

197 In the crude model, 20 metabolites were associated with Charcot's arthropathy at baseline before 198 multiple testing correction (p<0.05) but only 9 remained significant after correction ($p_{adjusted}<0.05$; 199 Figure 1, Supplementary Figure 4.1.1.1 and Table 4.1.1.2). In the M1 four amino acids (Proline, 200 Threonine, Valine, and Leucine) were negatively while six other metabolites were positively 201 associated with Charcot's arthropathy at baseline (padjusted<0.05; Figure 1, Supplementary Figure 202 4.1.2.1, and Table 4.1.2.2). In the M2 model, only proline remained associated ($p_{adjusted} < 0.05$) with 203 decreased incidence of Charcot's arthropathy (Figure 1, Supplementary figure 4.1.4.1 and Table 204 4.1.4.2).

Seventeen metabolites showed an association with amputations at baseline before multiple testing (p<0.05, Supplementary Table 5.1.1.2) in the crude model, while six remained significant after correction ($p_{adjusted}<0.05$). Of the six metabolites, five were positively associated (Ribonic acid,

Myo Inositol, 4-Hydroxybenzeneacetic acid, Ribitol, and Succinic acid) while amino acid Threonine was negatively correlated with amputations (Supplementary Figure 5.1.1.1). In the M1 model three metabolites showed a significant association with amputations at baseline before but none after the multiple testing correction (Supplementary Figure 5.1.2.1 and Table 5.1.2.2). None of the metabolites were associated with the incidence of DFUs at baseline after correcting for multiple testing in the crude or adjusted models ($p_{adjusted}$ >0.05; Supplementary Tables 6.1.1.3, 6.1.2.3, and 6.1.3.3).

215 Longitudinal analysis

All plasma metabolites used for cross-sectional analysis were examined for longitudinal analyses.

Albeit 17 circulating metabolites associated with the risk of incurring Charcot's arthropathy during follow-up in the crude model, only four metabolites (Ribonic acid, Ribitol, Creatinine, Myo Inositol) remained significant (Supplementary Figure 4.2.1.1 and Table 4.2.1.2) after multiple testing correction. In the M1 model out of 16 metabolites associated to risk of incurring Charcot's arthropathy during follow up (p<0.05, Supplementary Table 4.2.2.2), none retained after multiple testing correction. Similarly, no metabolites remained significant in M3.

None of the tested metabolites were associated with risk of incurring an amputation during followup in crude or adjusted models (p_{adjusted}>0.05; supplementary Tables 5.2.1.2, 5.2.2.2, and 5.2.3.2).

In the crude model 11 metabolites were significantly associated ($p_{adjusted} < 0.05$) to the risk of incurring a DFU during follow-up (Supplementary Figure 6.2.1.1 and Table 6.2.1.2). In the M1 model two metabolites (Ribonic acid and Tyrosine) remained significantly associated with risk of incurring DFU during follow-up (Supplementary Figure 6.2.2.1 and Table 6.2.2.2). Ribonic acid retained a significant association with risk of incurring a DFU during follow-up with a hazard ratio of 1.39 (1.08-1.8 (p=0.012) (Supplementary Section 6.2.3.3 and Figure 6.2.3.3.1)) after adjustment for renal function.

232 A survival analysis of DFU-free days stratified on median plasma levels of Ribonic acid in the

- study population showed a significantly higher number of DFU-free days in the group with the
- lowest levels of Ribonic acid in serum at baseline (p < 0.0001) (Figure 2).

235 Overall associations of significant metabolites and diabetic foot complication outcomes from the

crude model have been depicted in Figure 3 chord diagram.

237 Validation

238 We replicated Ribonic acid association with DFU in the cross-sectional validation study with 126

T1D individuals: 27 with DFU and 99 without any DFU (ESM Table 3).

Higher circulating Ribonic acid levels were significantly associated with DFU risk in the crude (Beta: 0.57; p = 0.013), M1 (Beta: 0.57; p=0.019) and M2 (Beta: 0.53; p=0.024) models, respectively (ESM Table 4; ESM figure 1).

243 **Discussion**

244 This is one of the first prospective studies to examine a possible correlation between circulating 245 plasma metabolites and diabetic foot complications. Several metabolites with association to 246 incidence and risk of incurring diabetic foot complications are identified in the current study. 247 Perhaps the most interesting being Ribonic acid also known as Ribonate, a derivate of the sugar 248 Ribose and part of the pentose pathway. A significant association between risk of incurring a DFU 249 and plasma levels of Ribonic acid. Prior studies have associated Ribonic acid with the incidence and 250 future risk of retinopathy and nephropathy in the same cohort examined here(17; 19). This may hint 251 at general correlation between complications associated with diabetes and plasma levels of Ribonic 252 acid in this one cohort. While this may still be true, a study by Chen et al. identified an association 253 between plasma levels of Ribonic acid and retinopathy when comparing a population with diabetes 254 and retinopathy to a population with diabetes without retinopathy(20). Similarly, Hu et al. found 255 that all-cause mortality was linked to plasma levels of Ribonic acid in a population with chronic

kidney disease(21). A possible role for Ribonic acid and/or the pentose pathway, as a marker of diabetes, is further supported by animal models that have shown that Ribonic acid levels in urine and plasma are elevated when diabetes is induced(22; 23). Although the proposed role of the pentose pathway and Ribonic acid is still unclear, it is a candidate for future research both when looking for potential biomarker and metabolomic pathways to target, in treatment and prevention of diabetic foot complications.

262

263 In addition to the connection between Ribonic acid and development of DFUs, an inverse 264 association between plasma levels of four amino acids (Threonine, Leucine, Valine, and Proline) 265 and incidence Charcot's arthropathy at baseline was found. Like Ribonic acid the role of circulating 266 amino acids in diabetes complications is unclear. There have been studies showing a vital role for amino acids in human metabolic pathways including gluconeogenesis(24-26) and the secretion of 267 268 insulin and glucagon(27). In regard to diabetic complications and circulating amino acids the 269 published data is sparse for foot related complications albeit associations to microvascular 270 complications (nephropathy and autonomic neuropathy) have been shown (10; 28-30). A recent 271 study by Hung et al. found an association between DFU healing and plasma levels of four amino 272 acids. These amino acids included Threonine and Leucine, which were also found in our study(31). 273 An association between amino acids and healing of pressure, trauma and burn ulcers have been 274 proposed in other studies(32; 33). Prospective randomized studies have even hinted at beneficial 275 effects on pressure-ulcer healing of nutritional supplements including specific amino acids(34). 276 However, the beneficial effects are still uncertain due to the limited available data(35). Similar 277 results have been seen when adding nutritional supplements to treatment of individuals with 278 diabetes; smaller retrospective and prospective studies have shown promise(36; 37), but the 279 combined data is insufficient to conclude if there is a beneficial effect (38). While the role of diet in

diabetic foot complications is still unclear, the role of diet in diabetes in general is not up for debate(39). We need further studies on the association between diabetic foot complications and amino acids to identify the most potent biomarkers and targets for treatment and prevention of diabetic foot complications.

284 Study limitations included missing information on medication. Consequently, information on 285 dosage and changes in dosage during the study is unavailable. In addition, information on some of 286 the known clinical risk factors (toe blood pressure and foot deformities) in development of diabetic 287 foot complications were unavailable at the time of data analysis. Finally, information on diet, which 288 may affect the composition of the individual participants metabolome, was unavailable. On the 289 other hand, the strengths of this study are, the large size of the cohort with T1D, long follow-up, 290 high throughput metabolomic measurements using mass spectrometry and high qualitative 291 bioinformatic data analyses methods.

292

293 A recent editorial from our institute highlights the importance of including longitudinal follow-up, 294 as presented in this study, in metabolomic and similar studies on diabetes and its complications(40). 295 This study adds to the growing evidence base for specific metabolites associated to complications of 296 diabetes, specifically DFU and Charcot's arthropathy. The identified circulating metabolites have 297 already been described in the literature, suggesting associations with diabetes and microvascular 298 complications. Plasma metabolomics in diabetic foot complications is an intriguing prospect, as risk 299 profiling promises the opportunity to prevent rather than treat these debilitating ailments. In 300 addition, metabolomics can help uncover molecular pathways of foot complication development, 301 that are also potential targets for developing novel therapeutics.

302

303

304 Acknowledgments

- 305 We thank the participants of this study. Jonas A. Andersen, and Tarunveer S. Ahluwalia are the
- 306 guarantors of this study.

307 Funding

- 308 TSA was supported by funding from the Novo Nordisk Foundation NNF18OC0052457 and Steno
- 309 Diabetes Center Copenhagen.
- 310

311 Author Contributions

- 312 Conceptualization: JAA, PR, TSA
- 313 Methodology: TS, KT, IM, CLQ, TSA
- 314 Investigation: JAA, TS, MJR-L, TSA
- 315 Visualization: TS
- 316 Funding acquisition: ST, PR, CLQ, TSA
- 317 Project administration: ST, AR, MFM, PR, TSA
- 318 Supervision: TSA
- 319 Writing original draft: JAA, TS, TSA
- 320 Writing review & editing: JAA, TS, ST, AR, MFM, PR, CLQ, TSA
- 321 All authors read and approved the final version of the manuscript.
- 322
- 323
- 324

325 **Competing interests**

- 326 None of the authors have any competing interest connected to this study.
- 327 *Outside of this study:* PR has received consultancy and/or speaking fees (to SDCC) from AbbVie,
- 328 Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, MSD, Novo Nordisk and
- 329 Sanofi Aventis, and research grants from Novo Nordisk and Astra Zeneca.

330 MFM has received speaking fees from Boehringer Ingelheim, Novartis, Baxter and Sanofi

Data availability

- 332 The data sets used in this study are available from the corresponding author after acquiring required
- 333 permissions from the relevant regulatory authorities.
- 334

335 **References**

- 336 1. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and
- direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res
 2020;13:16
- 2. Fauzi AA, Chung TY, Latif LA. Risk factors of diabetic foot Charcot arthropathy: a case-control study at a
- 340 Malaysian tertiary care centre. Singapore Med J 2016;57:198-203
- 341 3. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. J Clin Orthop Trauma
- 342 2021;17:88-93
- 343 4. IDF Diabetes Atlas [article online], 2021. Available from <u>https://diabetesatlas.org/</u>. Accessed 22/11-2021
 344 2021
- 5. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S, Bommer C, Esteghamati A, Ogurtsova
- 346 K, Zhang P, Colagiuri S. Global and regional estimates and projections of diabetes-related health
- expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes ResClin Pract 2020;162:108072
- 6. Kerr M, Barron E, Chadwick P, Evans T, Kong WM, Rayman G, Sutton-Smith M, Todd G, Young B, Jeffcoate
- WJ. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med
 2019;36:995-1002
- 352 7. Parker CN, Van Netten JJ, Parker TJ, Jia L, Corcoran H, Garrett M, Kwok CF, Nather A, Que MT, Srisawasdi
- 353 G, Wraight P, Lazzarini PA. Differences between national and international guidelines for the management
- 354 of diabetic foot disease. Diabetes Metab Res Rev 2019;35:e3101
- 8. Long J, Yang Z, Wang L, Han Y, Peng C, Yan C, Yan D. Metabolite biomarkers of type 2 diabetes mellitus
 and pre-diabetes: a systematic review and meta-analysis. BMC Endocr Disord 2020;20:174
- 357 9. Arneth B, Arneth R, Shams M. Metabolomics of Type 1 and Type 2 Diabetes. Int J Mol Sci 2019;20
- 358 10. Jin Q, Ma RCW. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological
- 359 Studies. Cells 2021;10
- 360 11. Tofte N, Suvitaival T, Ahonen L, Winther SA, Theilade S, Frimodt-Moller M, Ahluwalia TS, Rossing P.
- 361 Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal
- 362 impairment and all-cause mortality in type 1 diabetes. Sci Rep 2019;9:16398
- 363 12. Clos-Garcia M, Ahluwalia TS, Winther SA, Henriksen P, Ali M, Fan Y, Stankevic E, Lyu L, Vogt JK, Hansen
- T, Legido-Quigley C, Rossing P, Pedersen O. Multiomics signatures of type 1 diabetes with and without
- 365 albuminuria. Front Endocrinol (Lausanne) 2022;13:1015557
- 366 13. ICD-10 Version:2010 [article online], 2010. Available from https://icd.who.int/browse10/2010/en.
 367 Accessed 09/02-2022 2022
- 368 14. DNBo. H. Diabetic Foot Ulcers a health technology assessment. Copenhagen: Danish National Board of 369 Health, 2011 2011;
- 370 15. Sundhedsvæsenets Klassifikations System (SKS) [article online], 2021. Available from
- 371 <u>https://sundhedsdatastyrelsen.dk/da/rammer-og-retningslinjer/om-klassifikationer/sks-klassifikationer.</u>
- 372 Accessed 09/02-2022 2022

- 16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F,
- Zhang YL, Coresh J, Levey AS, Investigators C-E. Estimating glomerular filtration rate from serum creatinine
 and cystatin C. N Engl J Med 2012;367:20-29
- 376 17. Tofte N, Suvitaival T, Trost K, Mattila IM, Theilade S, Winther SA, Ahluwalia TS, Frimodt-Møller M,
- 377 Legido-Quigley C, Rossing P. Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain
- 378 Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons
- With Type 1 Diabetes. Front Endocrinol (Lausanne) 2019;10:818
- 380 18. Castillo S, Mattila I, Miettinen J, Orešič M, Hyötyläinen T. Data analysis tool for comprehensive two-
- dimensional gas chromatography/time-of-flight mass spectrometry. Anal Chem 2011;83:3058-3067
- 382 19. Curovic VR, Suvitaival T, Mattila I, Ahonen L, Trost K, Theilade S, Hansen TW, Legido-Quigley C, Rossing
- P. Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1
 Diabetes. Diabetes 2020;69:2217-2226
- 385 20. Chen L, Cheng CY, Choi H, Ikram MK, Sabanayagam C, Tan GS, Tian D, Zhang L, Venkatesan G, Tai ES,
- Wang JJ, Mitchell P, Cheung CM, Beuerman RW, Zhou L, Chan EC, Wong TY. Plasma Metabonomic Profiling
 of Diabetic Retinopathy. Diabetes 2016;65:1099-1108
- 388 21. Hu JR, Coresh J, Inker LA, Levey AS, Zheng Z, Rebholz CM, Tin A, Appel LJ, Chen J, Sarnak MJ, Grams ME.
- Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int
 2018;94:381-389
- 391 22. Jing L, Chengji W. GC/MS-based metabolomics strategy to analyze the effect of exercise intervention in
 392 diabetic rats. Endocr Connect 2019;8:654-660
- 393 23. Steer KA, Sochor M, McLean P. Renal hypertrophy in experimental diabetes. Changes in pentose
- 394 phosphate pathway activity. Diabetes 1985;34:485-490
- 24. Schutz Y. Protein turnover, ureagenesis and gluconeogenesis. Int J Vitam Nutr Res 2011;81:101-107
- 396 25. Basu R, Chandramouli V, Dicke B, Landau B, Rizza R. Obesity and type 2 diabetes impair insulin-induced
- 397 suppression of glycogenolysis as well as gluconeogenesis. Diabetes 2005;54:1942-1948
- 398 26. Chung ST, Hsia DS, Chacko SK, Rodriguez LM, Haymond MW. Increased gluconeogenesis in youth with 399 newly diagnosed type 2 diabetes. Diabetologia 2015;58:596-603
- 400 27. Gannon MC, Nuttall FQ. Amino acid ingestion and glucose metabolism--a review. IUBMB Life
- 401 2010;62:660-668
- 402 28. Mathew AV, Jaiswal M, Ang L, Michailidis G, Pennathur S, Pop-Busui R. Impaired Amino Acid and TCA
- 403 Metabolism and Cardiovascular Autonomic Neuropathy Progression in Type 1 Diabetes. Diabetes
- 404 2019;68:2035-2044
- 405 29. Hansen CS, Suvitaival T, Theilade S, Mattila I, Lajer M, Trost K, Ahonen L, Hansen TW, Legido-Quigley C,
- 406 Rossing P, Ahluwalia TS. Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With
- 407 Disturbances in TCA, Lipid, and Glucose Metabolism. Front Endocrinol (Lausanne) 2022;13:831793
- 408 30. Tofte N, Vogelzangs N, Mook-Kanamori D, Brahimaj A, Nano J, Ahmadizar F, van Dijk KW, Frimodt-
- 409 Moller M, Arts I, Beulens JWJ, Rutters F, van der Heijden AA, Kavousi M, Stehouwer CDA, Nijpels G, van
- 410 Greevenbroek MMJ, van der Kallen CJH, Rossing P, Ahluwalia TS, t Hart LM. Plasma Metabolomics Identifies
- 411 Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes. J Clin
- 412 Endocrinol Metab 2020;105
- 413 31. Hung SY, Tsai JS, Yeh JT, Chen KH, Lin CN, Yang HM, Lin CW, Chen HY, Huang CH, Huang YY. Amino acids
- 414 and wound healing in people with limb-threatening diabetic foot ulcers. J Diabetes Complications
- 415 2019;33:107403
- 416 32. Wong A, Chew A, Wang CM, Ong L, Zhang SH, Young S. The use of a specialised amino acid mixture for
- 417 pressure ulcers: a placebo-controlled trial. J Wound Care 2014;23:259-260, 262-254, 266-259
- 418 33. Stechmiller JK. Understanding the role of nutrition and wound healing. Nutr Clin Pract 2010;25:61-68
- 419 34. Cereda E, Neyens JCL, Caccialanza R, Rondanelli M, Schols J. Efficacy of a Disease-Specific Nutritional
- 420 Support for Pressure Ulcer Healing: A Systematic Review and Meta-Analysis. J Nutr Health Aging
- 421 2017;21:655-661

- 422 35. Langer G, Fink A. Nutritional interventions for preventing and treating pressure ulcers. Cochrane
- 423 Database Syst Rev 2014:Cd003216
- 424 36. Armstrong DG, Hanft JR, Driver VR, Smith AP, Lazaro-Martinez JL, Reyzelman AM, Furst GJ, Vayser DJ,
- 425 Cervantes HL, Snyder RJ, Moore MF, May PE, Nelson JL, Baggs GE, Voss AC. Effect of oral nutritional
- 426 supplementation on wound healing in diabetic foot ulcers: a prospective randomized controlled trial.
- 427 Diabet Med 2014;31:1069-1077
- 428 37. Sipahi S, Gungor O, Gunduz M, Cilci M, Demirci MC, Tamer A. The effect of oral supplementation with a
- 429 combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine on wound healing: a
- 430 retrospective analysis of diabetic haemodialysis patients. BMC Nephrol 2013;14:8
- 431 38. Moore ZE, Corcoran MA, Patton D. Nutritional interventions for treating foot ulcers in people with
- 432 diabetes. Cochrane Database Syst Rev 2020;7:CD011378
- 433 39. Diabetes Prevention [article online], 2022. Available from
- 434 <u>https://www.idf.org/aboutdiabetes/prevention.html</u>. Accessed 09/02-2022 2022
- 435 40. Ahluwalia TS, Kilpelainen TO, Singh S, Rossing P. Editorial: Novel Biomarkers for Type 2 Diabetes. Front
- 436 Endocrinol (Lausanne) 2019;10:649
- 437
- 438
- 439
- 440
- 441
- . . .
- 442
- 443
- 444
- 445
- 446
- 447
- 448
- 449
- 450
- 451
- 452
- 453
- 454

455

456

457 **Tables and figures**

458 **Table 1.** Clinical characteristics of the study participants at baseline

	All study participants	T1D participants without foot complications	T1D with at least one foot complication	p-value*
<i>n</i> (%)	637 (100)	577 (90.6)	60 (9.4)	-
Men, <i>n</i> (%)	348 (54.6)	314 (54.4)	34 (56.6)	0.8
Age, years	55 (47, 64)	55 (47, 63)	60 (52, 68)	<0.001
Diabetes duration (years)	35 (25, 44)	34 (23, 43)	44 (36, 52)	<0.001
Smokers, n (%)	133 (20.8)	123 (21.3)	10 (16.6)	0.4
BMI, kg/m ²	24.8 (22.5, 27.5)	24.8 (22.5, 27.2)	25.3 (22.7, 29.1)	0.6
Systolic blood pressure,	130 (119, 142)	129 (118, 142)	131 (120, 148)	0.4
mmHg				
HbA _{1c} , mmol/mol	64 (56, 72)	64 (55, 72)	66 (58, 72)	0.2
eGFR, ml/min/1.73 m ²	85 (64, 102)	86 (68, 104)	59 (43, 88)	<0.001
UACR, mg/g	13 (6, 42)	12 (6, 39)	41 (20, 206)	<0.001
LDL, mmol/l	2.4 (2.0, 2.9)	2.4 (2.0, 2.9)	2.1 (1.7, 2.6)	0.089
Triglycerides, mmol/l	1.0 (0.7, 1.3)	1.0 (0.7, 1.4)	0.9 (0.8, 1.2)	0.8
DFC, n	68	-	68	-
DFU, <i>n</i> (%)	19 (3)	-	19 (31.6)	-
Amputations, <i>n</i> (%)	23 (3.6)	-	23 (38.3)	-
Charcot's arthropathy, <i>n</i> (%)	26 (4.1)	-	26 (43.3)	-

459 Values are Median (IQR).

460 T1D: Type 1 Diabetes; BMI: Body mass index; HbA_{1c}: Glycosylated hemoglobin A1c; eGFR: Estimated

461 glomerular filtration rate; LDL: Low density lipoproteins; UACR: urinary albumin excretion rate; DFC:

462 Diabetic foot complication comprising diagnosis of diabetic foot ulcer (DFU), amputations, or Charcot's
 463 arthropathy.

464 *P value <0.05 were considered significant and are depicted in bold. P values were calculated using Welch

465 Two Sample t-test; Fisher's exact test; or Pearson's Chi-squared test.

466

467

468

469

470

- 471
- 472

473 Figure Legends

474 Figure 1. Cross-sectional analysis - Charcot's Arthropathy

475 Cross-sectional analysis of association between baseline metabolites level and Charcot's arthropathy at 476 baseline. Divided in crude (with correction for multiple testing), adjusted (further adjusted for age, gender, 477 body mass index, systolic blood pressure, cholesterol, glycosylated hemoglobin A1c, smoking, statin and 478 triglycerides) and fully-adjusted (further adjusted for estimated glomerular filtration rate (eGFR) and 479 urinary-albumin creatinine ratio), with 95% confidence intervals. Significance was defined as p < 0.05. In this 480 figure an significant p-value not adjusted for multiple testing is marked in yellow (p). A p-value that is 481 significant after adjustment for multiple testing is marked in red (q). Finally, a p-value that is not-significant 482 before multiple testing is marked in black.

483

484 **Figure 2.** Survival analysis – *diabetic foot ulcer-free days*

Kaplan-Meier analysis of ulcer-free days stratified on median of plasma levels of Ribonic acid at baseline.

Figure 3. Overview of serum metabolite associations with diabetic foot complications (incident and
 prevalent; crude model).

489

490 Chord diagram of crude associations between the metabolome (left) and foot complications (right) at

491 baseline (prevalent cases) and during the follow-up (incident cases). A curve between a metabolite and a

492 complication depicts a significant crude association (red: positive; blue: negative) after correction for

493 multiple testing. The category of each metabolite is indicated by the color aside the metabolite name. Amino

494 acids Leucine, Proline, Threonine and Valine are negatively associated with prevalent Charcot's arthropathy

495 (blue curves), whereas most of the other associations are positive (red curves).

496

Significance - q < 0.05 - p < 0.05 - Not significant





